FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891863963> ?p ?o ?g. }

• W2891863963 endingPage "277" @default.
• W2891863963 startingPage "269" @default.
• W2891863963 abstract "Anticancer peptides (ACPs) are cationic amphiphiles that preferentially kill cancer cells through folding-dependent membrane disruption. Although ACPs represent attractive therapeutic candidates, particularly against drug-resistant cancers, their successful translation into clinical practice has gone unrealized due to their poor bioavailability, serum instability and, most importantly, severe hemolytic toxicity. Here, we exploit the membrane-specific interactions of ACPs to prepare a new class of peptide-lipid particle, we term a lipopeptisome (LP). This design sequesters loaded ACPs within a lipid lamellar corona to avoid contact with red blood cells and healthy tissues, while affording potent lytic destruction of cancer cells following LP-membrane fusion. Biophysical studies show ACPs rapidly fold at, and integrate into, liposomal membranes to form stable LPs with high loading efficiencies (>80%). Rational design of the particles to possess lipid combinations mimicking that of the aberrant cancer cell outer leaflet allows LPs to rapidly fuse with tumor cell membranes and afford localized assembly of loaded ACPs within the bilayer. This leads to preferential fusolytic killing of cancer cells with minimal collateral toxicity towards non-cancerous cells and erythrocytes, thereby imparting clinically relevant therapeutic indices to otherwise toxic ACPs. Thus, integration of ACPs into self-assembled LPs represents a new delivery strategy to improve the therapeutic utility of oncolytic agents, and suggests this technology may be added to targeted combinatorial approaches in precision medicine. Despite their significant clinical potential, the therapeutic utility of many ACPs has been limited by their collateral hemolysis during administration. Leveraging the membrane-specific interactions of ACPs, here we prepare self-assembled peptide-lipid nanoparticles, or ‘lipopeptisomes’ (LPs), capable of preferentially fusing with and lysing cancer cell membranes. Key to this fusolytic action is the construction of LPs from lipids simulating the cancer cell outer leaflet. This design recruits the oncolytic peptide payload into the carrier lamella and allows for selective destruction of cancer cells without disrupting healthy cells. Consequently, LPs impart clinically relevant therapeutic indexes to previously toxic ACPs, and thus open new opportunities to improve the clinical translation of oncolytics challenged by narrow therapeutic windows." @default.
• W2891863963 created "2018-09-27" @default.
• W2891863963 creator A5027004504 @default.
• W2891863963 creator A5047201030 @default.
• W2891863963 creator A5062086882 @default.
• W2891863963 creator A5073182918 @default.
• W2891863963 creator A5083185664 @default.
• W2891863963 date "2018-10-01" @default.
• W2891863963 modified "2023-10-17" @default.
• W2891863963 title "Lipopeptisomes: Anticancer peptide-assembled particles for fusolytic oncotherapy" @default.
• W2891863963 cites W1526178345 @default.
• W2891863963 cites W165853039 @default.
• W2891863963 cites W1967110384 @default.
• W2891863963 cites W1967729931 @default.
• W2891863963 cites W1980568044 @default.
• W2891863963 cites W1990356838 @default.
• W2891863963 cites W1992155193 @default.
• W2891863963 cites W1995873775 @default.
• W2891863963 cites W2001532006 @default.
• W2891863963 cites W2011714769 @default.
• W2891863963 cites W2012815507 @default.
• W2891863963 cites W2022066534 @default.
• W2891863963 cites W2024001544 @default.
• W2891863963 cites W2030624081 @default.
• W2891863963 cites W2031173603 @default.
• W2891863963 cites W2031762792 @default.
• W2891863963 cites W2034517648 @default.
• W2891863963 cites W2037876225 @default.
• W2891863963 cites W2042198735 @default.
• W2891863963 cites W2042331997 @default.
• W2891863963 cites W2042712121 @default.
• W2891863963 cites W2071565763 @default.
• W2891863963 cites W2076226743 @default.
• W2891863963 cites W2078412922 @default.
• W2891863963 cites W2082890710 @default.
• W2891863963 cites W2113792431 @default.
• W2891863963 cites W2125872855 @default.
• W2891863963 cites W2142616277 @default.
• W2891863963 cites W2147531177 @default.
• W2891863963 cites W2153099927 @default.
• W2891863963 cites W2179712017 @default.
• W2891863963 cites W2252983692 @default.
• W2891863963 cites W2265836483 @default.
• W2891863963 cites W2320737177 @default.
• W2891863963 cites W243953374 @default.
• W2891863963 cites W2572038639 @default.
• W2891863963 cites W2591017015 @default.
• W2891863963 cites W2735995142 @default.
• W2891863963 cites W3155828254 @default.
• W2891863963 cites W318616184 @default.
• W2891863963 cites W4206739117 @default.
• W2891863963 doi "https://doi.org/10.1016/j.actbio.2018.09.025" @default.
• W2891863963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30240951" @default.
• W2891863963 hasPublicationYear "2018" @default.
• W2891863963 type Work @default.
• W2891863963 sameAs 2891863963 @default.
• W2891863963 citedByCount "20" @default.
• W2891863963 countsByYear W28918639632019 @default.
• W2891863963 countsByYear W28918639632020 @default.
• W2891863963 countsByYear W28918639632021 @default.
• W2891863963 countsByYear W28918639632022 @default.
• W2891863963 countsByYear W28918639632023 @default.
• W2891863963 crossrefType "journal-article" @default.
• W2891863963 hasAuthorship W2891863963A5027004504 @default.
• W2891863963 hasAuthorship W2891863963A5047201030 @default.
• W2891863963 hasAuthorship W2891863963A5062086882 @default.
• W2891863963 hasAuthorship W2891863963A5073182918 @default.
• W2891863963 hasAuthorship W2891863963A5083185664 @default.
• W2891863963 hasConcept C109316439 @default.
• W2891863963 hasConcept C121608353 @default.
• W2891863963 hasConcept C12554922 @default.
• W2891863963 hasConcept C185592680 @default.
• W2891863963 hasConcept C192562407 @default.
• W2891863963 hasConcept C202751555 @default.
• W2891863963 hasConcept C203014093 @default.
• W2891863963 hasConcept C2779902561 @default.
• W2891863963 hasConcept C39944091 @default.
• W2891863963 hasConcept C41625074 @default.
• W2891863963 hasConcept C502942594 @default.
• W2891863963 hasConcept C54355233 @default.
• W2891863963 hasConcept C55493867 @default.
• W2891863963 hasConcept C73588182 @default.
• W2891863963 hasConcept C86803240 @default.
• W2891863963 hasConcept C96232424 @default.
• W2891863963 hasConceptScore W2891863963C109316439 @default.
• W2891863963 hasConceptScore W2891863963C121608353 @default.
• W2891863963 hasConceptScore W2891863963C12554922 @default.
• W2891863963 hasConceptScore W2891863963C185592680 @default.
• W2891863963 hasConceptScore W2891863963C192562407 @default.
• W2891863963 hasConceptScore W2891863963C202751555 @default.
• W2891863963 hasConceptScore W2891863963C203014093 @default.
• W2891863963 hasConceptScore W2891863963C2779902561 @default.
• W2891863963 hasConceptScore W2891863963C39944091 @default.
• W2891863963 hasConceptScore W2891863963C41625074 @default.
• W2891863963 hasConceptScore W2891863963C502942594 @default.
• W2891863963 hasConceptScore W2891863963C54355233 @default.
• W2891863963 hasConceptScore W2891863963C55493867 @default.
• W2891863963 hasConceptScore W2891863963C73588182 @default.

• next